Computed Tomography

Cardiac computed tomography (CT) has become a primary cardiovascular imaging modality in the past 20 years, and was recommended as a 1A recommendation in the 2021 chest pain assessment guidelines. CT calcium scoring has became a primary risk assessment for coronary artery disease and whether patients should be on statins. Coronary CT angiography (CCTA) is used to for anatomical assessment of the arteries for plaque burden and to identify areas of blockage that may cause ischemia and heart attacks. Additional use of contrast CT perfusion or fractional flow reserve CT (FFR-CT) can offer physiological information on the function of the heart. CT plays a primary role in structural heart assessments for heart valves, repair of congenital defects and left atrial appendage occlusion (LAAO) for both pre-procedure planning and procedural guidance. Find more news on general radiology CT use.

Heartflow raises $364M with IPO, rings Nasdaq opening bell
Heartflow has officially gone public after selling more than 19 million shares of common stock during an upsized IPO. The California medtech company, known for its AI-powered CCTA evaluations, is now being traded on Nasdaq under the symbol HTFL.
Pericarditis: New guidance takes on the diagnosis and management of a challenging heart condition
Pericarditis, inflammation of the pericardium, accounts for approximately 5% of all emergency department evaluations for chest pain. These new recommendations are designed to help guide clinicians through the ins and outs of patient care.
Cardiovascular IT systems keep evolving with AI, Epic integration on the rise
A Signify Research representative highlights key trends in cardiovascular IT systems, including the growing role of AI and much more.
CCTA outperforms TEE after LAAO, new meta-analysis confirms
Researchers reviewed data from more than 1,300 patients who underwent both CCTA and TEE after undergoing LAAO. The two modalities were comparable in many ways, but cardiac CT was linked to a few key benefits.
CCTA could make invasive angiography a thing of the past
John Puskas, MD, thinks coronary CT angiography is on its way to completely transforming patient care.

Heartflow president and CEO John Farquhar celebrate the company's IPO by ringing Nasdaq's the ceremonial opening bell.

Heartflow raises $364M with IPO, rings Nasdaq opening bell

Heartflow has officially gone public after selling more than 19 million shares of common stock during an upsized IPO. The California medtech company, known for its AI-powered CCTA evaluations, is now being traded on Nasdaq under the symbol HTFL.

Pericarditis: New guidance takes on the diagnosis and management of a challenging heart condition

Pericarditis, inflammation of the pericardium, accounts for approximately 5% of all emergency department evaluations for chest pain. These new recommendations are designed to help guide clinicians through the ins and outs of patient care.

Healthcare IT analyst Amy Thompson from Signify Research explains trends in cardiology information systems at ACC 2025.

Cardiovascular IT systems keep evolving with AI, Epic integration on the rise

A Signify Research representative highlights key trends in cardiovascular IT systems, including the growing role of AI and much more.

CCTA outperforms TEE after LAAO, new meta-analysis confirms

Researchers reviewed data from more than 1,300 patients who underwent both CCTA and TEE after undergoing LAAO. The two modalities were comparable in many ways, but cardiac CT was linked to a few key benefits.

Cardiac surgeon John Puskas, MD, Emory University, says CCTA will make invasive angiography obsolete very soon.

CCTA could make invasive angiography a thing of the past

John Puskas, MD, thinks coronary CT angiography is on its way to completely transforming patient care.

Video interview with Allen Taylor, MD, chairman of cardiology at Medstar, who explains use of AI CCTA plaque analysis at Medstar to improve risk assessments.

AI software takes cardiac risk assessments to another level

Allen Taylor, MD, thinks AI-powered plaque evaluations can make a substantial impact on patient care.

Heartflow, a leader in AI-powered imaging evaluations, files for IPO

Heartflow, known for its AI-based CCTA evaluations, appears to be going public. The news follows years of momentum for the California-based company, including improved Medicare reimbursements for cardiac CT and a new Category I CPT code for its Plaque Analysis software.

New data highlight how Heartflow's AI software drives major shifts in heart care

One of the study's most significant findings was that patients managed using the advanced AI software saw LDL cholesterol drops of 18.7 mg/dL, with a 15% reduction in their risk of a cardiac event. Even patients with no calcified plaque saw significant changes in care management.